Skip to main content

Table 1 Baseline patient characteristics

From: Surgery time interval and molecular subtype may influence Ki67 change after core needle biopsy in breast cancer patients

Characteristic No. Percent
Age, years 56.6 (24-91)
 <40 20 7.2
 40-49 64 23.2
 50-70 155 56.2
 >70 37 13.4
Menstrual status
 Peri/pre-menopause 89 32.2
 Post-menopause 187 67.8
Breast surgery type
 Mastectomy (+/−reconstruction) 239 86.6
 Lumpectomy 37 13.4
Pathological type   
 Invasive ductal carcinoma 246 89.1
 Invasive lobular carcinoma 12 4.3
 Others 18 6.5
Tumor size
 Tx 5 1.8
 ≤2 cm 118 42.8
 2-5 cm 147 53.3
 >5 cm 6 2.2
Axillary lymph node
 Negative 155 56.2
 Positive 121 43.8
Histologic grading   
 I 6 2.2
 II 134 48.6
 III 90 32.6
 NA 46 16.7
Estrogen Receptor   
 Negative 62 22.5
 Positive 214 77.5
Progesterone Receptor   
 Negative 113 40.9
 Positive 163 59.1
Hormonal Receptor   
 Negative 61 22.1
 Positive 215 77.9
HER2   
 Negative 217 78.6
 Positive 59 21.4
Ki67 (%, mean) 26.2 (1-90)
 <20 129 46.7
 ≥20 147 53.3
Molecular subtype   
 Luminal A 73 26.4
 Luminal B-HER2- 109 39.5
 Luminal B-HER2+ 33 12.0
 Triple negative 35 12.7
 HER2 positive 26 9.4
Surgery time interval (days) 4.5 (1-37)
 1-2 55 19.9
 3-4 113 40.9
 ≥5 108 39.1
  1. Abbreviation: NA not available